A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme

Caelyx in patients with recurrent glioblastoma multiforme

Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established activity in a broad range of tumors but has not been extensively evaluated in the treatment of GBM. Phase 1 data suggest that temozolomide and Caelyx can be combined safely at full dose. In this phase 2 study, combination temozolomide (200 mg/m orally...

Radiothermotherapy for glioblastoma multiforme: A preliminary study

Introduction: Glioblastoma multiforme (GBM) is a highly radioresistant cancer with low survival rate. Current therapy approaches have failed to treat GBM. The aim of this study was to assess how GBM tumors respond to combination of hyperthermia and radiotherapy. Materials and Methods:   In this study, 38 GBM patients were included. 19 patients were treated ...

Glioblastoma Multiforme in Children, A Case-Report

ABSTRACT: Glioblastoma multiforme is the most malignant primary brain tumor .It usually occurs in the 5th and 6th decades of life and is rare in childern. In this paper a case of glioblastoma multiforme is reported in a ten year - old child who presented with two week's history of headache with no neurological defect.C.T scan revealed å right frontal mass with massive surrounding oedema. He w...

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.

PURPOSE To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy. PATIENTS AND METHODS Patients with newly diagnosed GBM received radiotherapy concurrently with...

Bevacizumab for recurrent glioblastoma multiforme